Hannah Cornman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hannah Cornman has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Shawn G. Kwatra
Department of Dermatology, University of Maryland School of Medicine, Baltimore, USA
13 shared publications - Anusha Kambala
Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
8 shared publications - Madan M. Kwatra
Department of Anesthesiology, Duke University School of Medicine, Durham, North Carolina, USA
8 shared publications - Emily Ma
Department of Dermatology, University of Maryland School of Medicine , Baltimore, MD
5 shared publications - Kevin K. Lee
Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
5 shared publications - Melika Marani
Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
5 shared publications
Latest Publications
- Open Access
- 18 October 2025
- Published byĀ ElsevierĀ inĀ JID Innovations
- Vol.Ā 6 Ā (1) , 100422
Nanostring Transcriptomic Analysis Highlights IL-6 Family and TGF-β Pathways in the Pathogenesis of Prurigo Nodularis
- 18 October 2025
- Published byĀ ElsevierĀ inĀ JID Innovations
- Vol.Ā 6 Ā (1) , 100422
Open AccessNanostring Transcriptomic Analysis Highlights IL-6 Family and TGF-β Pathways in the Pathogenesis of Prurigo Nodularis
- Open Access
- 12 April 2024
- Published byĀ ElsevierĀ inĀ JID Innovations
- Vol.Ā 4 Ā (4) , 100281
Dupilumab Therapy Modulates Circulating Inflammatory Mediators in Patients with Prurigo Nodularis
- 12 April 2024
- Published byĀ ElsevierĀ inĀ JID Innovations
- Vol.Ā 4 Ā (4) , 100281
Open AccessDupilumab Therapy Modulates Circulating Inflammatory Mediators in Patients with Prurigo Nodularis
- 24 March 2024
- Published byĀ ElsevierĀ inĀ Journal of Investigative Dermatology
- Vol.Ā 144 Ā (11) , 2501-2512.e4
Spatial Mass CytometryāBased Single-Cell Imaging Reveals a Disrupted EpithelialāImmune Axis in Prurigo Nodularis
- 24 March 2024
- Published byĀ ElsevierĀ inĀ Journal of Investigative Dermatology
- Vol.Ā 144 Ā (11) , 2501-2512.e4
Spatial Mass CytometryāBased Single-Cell Imaging Reveals a Disrupted EpithelialāImmune Axis in Prurigo Nodularis
- 4 March 2024
- Published byĀ ElsevierĀ inĀ Journal of Investigative Dermatology
- Vol.Ā 144 Ā (9) , 2085-2089.e1
Excoriation Disorder Is Characterized by Systemic Glutamatergic Dysfunction
- 4 March 2024
- Published byĀ ElsevierĀ inĀ Journal of Investigative Dermatology
- Vol.Ā 144 Ā (9) , 2085-2089.e1
Excoriation Disorder Is Characterized by Systemic Glutamatergic Dysfunction
- Top Cited Papers
- 12 February 2024
- Published byĀ Oxford University Press (OUP)Ā inĀ British Journal of Dermatology
- Vol.Ā 190 Ā (6) , 798-810
Prurigo nodularis: new insights into pathogenesis and novel therapeutics
Lay Summary: Prurigo nodularis (PN) is a chronic skin condition featuring extremely itchy nodules on the skin of the legs, arms and trunk of the body. PN affects approximately 72 per 100 000 people and the severe itch associated with the condition can negatively impact a personās sleep, work and social life. However, the cause of PN remains unclear. Current understanding of PN is based on imbalances in the immune system leading to widespread inflammation as well as dysregulation of the nerves in the skin. Immune molecules released from T cells [such as interleukin (IL)-4, -13, -31, -17, -22 and -31] increase systemic inflammation and are elevated in people with PN. Activated inflammatory cells (such as mast cells or eosinophils) may also release factors that promote inflammation, itch and neural changes within the skin. Neural dysregulation in PN features a lower density of itch-sensing nerve fibres in the epidermis (upper layer of the skin) and a higher density of itch-sensing nerve fibres in the dermis (lower layer of the skin). Because the pathogenesis of PN is not fully understood, the therapies available for PN have had limited success in reducing itch and nodules. The only drug currently approved for PN in the USA and Europe is dupilumab, an IL-4Rα inhibitor that blocks signalling through IL-4 and IL-13, which is undergoing post-marketing surveillance. Other new drugs are being assessed in various phases of clinical trials, including nemolizumab, vixarelimab, barzolvolimab, ruxolitinib, abrocitinib, povorcitinib and nalbuphine.
- 12 February 2024
- Published byĀ Oxford University Press (OUP)Ā inĀ British Journal of Dermatology
- Vol.Ā 190 Ā (6) , 798-810
Top Cited PapersPrurigo nodularis: new insights into pathogenesis and novel therapeutics
Lay Summary: Prurigo nodularis (PN) is a chronic skin condition featuring extremely itchy nodules on the skin of the legs, arms and trunk of the body. PN affects approximately 72 per 100 000 people and the severe itch associated with the condition can negatively impact a personās sleep, work and social life. However, the cause of PN remains unclear. Current understanding of PN is based on imbalances in the immune system leading to widespread inflammation as well as dysregulation of the nerves in the skin. Immune molecules released from T cells [such as interleukin (IL)-4, -13, -31, -17, -22 and -31] increase systemic inflammation and are elevated in people with PN. Activated inflammatory cells (such as mast cells or eosinophils) may also release factors that promote inflammation, itch and neural changes within the skin. Neural dysregulation in PN features a lower density of itch-sensing nerve fibres in the epidermis (upper layer of the skin) and a higher density of itch-sensing nerve fibres in the dermis (lower layer of the skin). Because the pathogenesis of PN is not fully understood, the therapies available for PN have had limited success in reducing itch and nodules. The only drug currently approved for PN in the USA and Europe is dupilumab, an IL-4Rα inhibitor that blocks signalling through IL-4 and IL-13, which is undergoing post-marketing surveillance. Other new drugs are being assessed in various phases of clinical trials, including nemolizumab, vixarelimab, barzolvolimab, ruxolitinib, abrocitinib, povorcitinib and nalbuphine.
- 3 February 2024
- Published byĀ Oxford University Press (OUP)Ā inĀ Clinical and Experimental Dermatology
- Vol.Ā 49 Ā (8) , 879-881
No increased risk of postoperative adverse events in patients with hidradenitis suppurativa following a total joint replacement
There is concern for increased risk of adverse events, particularly periprosthetic joint infection (PJI), following total joint replacement (TJR) in patients with hidradenitis suppurativa (HS) because of a compromised skin barrier and bacterial colonization of lesions. We used the TriNetX health research database to identify patients who had undergone TJR with (n = 1760) and without (n = 1760) HS matched by age, sex, ethnicity, race and risk factors for PJI. Multivariate analysis was performed and revealed that 90-day risk of PJI, reoperation, wound dehiscence, delayed wound healing, emergency room visits and readmission were not increased among patients with HS who underwent TJR. Given these findings, dermatologists and orthopaedists should not defer TJR access for patients with HS, as risk of postoperative complications is not prohibitive.
- 3 February 2024
- Published byĀ Oxford University Press (OUP)Ā inĀ Clinical and Experimental Dermatology
- Vol.Ā 49 Ā (8) , 879-881
No increased risk of postoperative adverse events in patients with hidradenitis suppurativa following a total joint replacement
There is concern for increased risk of adverse events, particularly periprosthetic joint infection (PJI), following total joint replacement (TJR) in patients with hidradenitis suppurativa (HS) because of a compromised skin barrier and bacterial colonization of lesions. We used the TriNetX health research database to identify patients who had undergone TJR with (n = 1760) and without (n = 1760) HS matched by age, sex, ethnicity, race and risk factors for PJI. Multivariate analysis was performed and revealed that 90-day risk of PJI, reoperation, wound dehiscence, delayed wound healing, emergency room visits and readmission were not increased among patients with HS who underwent TJR. Given these findings, dermatologists and orthopaedists should not defer TJR access for patients with HS, as risk of postoperative complications is not prohibitive.
- 23 January 2024
- Published byĀ Oxford University Press (OUP)Ā inĀ British Journal of Dermatology
- Vol.Ā 190 Ā (4) , 571-572
Severity, impact on quality of life and mental health burden of pruritus in prurigo nodularis: a cross-sectional study of a diverse patient cohort
Dear Editor, Prurigo nodularis (PN) is a chronic inflammatory skin disease characterized by intensely pruritic nodules and a significant disruption to quality of life (QoL).1 Black people are genetically predisposed to PN and disproportionately affected.1,2 Currently, the majority of studies that have examined the clinical severity of PN and its impact on QoL have been conducted in Europe.3 Given the differences between European and North American populations, and in the disease burden and pathophysiology of PN, it is important to assess these factors in a diverse population.4 Here, we performed a cross-sectional analysis of disease severity and QoL measures in a diverse cohort of patients with PN from the USA. Eligible participants were aged ā„ 18 years with a dermatologist diagnosis of PN presenting to the Johns Hopkins Itch Center between August 2017 and April 2019. Patients completed a paper-based survey that included two QoL instruments [Dermatology Life Quality Index (DLQI) and ItchyQoL], two pruritus-Āspecific severity instruments [worst-itch numerical rating scale (WI-NRS) and 5-D Pruritus Scale] and the Beck Depression Inventory (BDI). In total, 40 patients were surveyed. Demographic characteristics were collected by patient self-report and confirmed via medical records. Statistical analysis was performed in Stata version 15 (StataCorp, College Station, TX, USA). Differences between groups were determined by MannāWhitney U tests. Two sample t-tests with unequal variances were employed to compare mean QoL scores with published scores.
- 23 January 2024
- Published byĀ Oxford University Press (OUP)Ā inĀ British Journal of Dermatology
- Vol.Ā 190 Ā (4) , 571-572
Severity, impact on quality of life and mental health burden of pruritus in prurigo nodularis: a cross-sectional study of a diverse patient cohort
Dear Editor, Prurigo nodularis (PN) is a chronic inflammatory skin disease characterized by intensely pruritic nodules and a significant disruption to quality of life (QoL).1 Black people are genetically predisposed to PN and disproportionately affected.1,2 Currently, the majority of studies that have examined the clinical severity of PN and its impact on QoL have been conducted in Europe.3 Given the differences between European and North American populations, and in the disease burden and pathophysiology of PN, it is important to assess these factors in a diverse population.4 Here, we performed a cross-sectional analysis of disease severity and QoL measures in a diverse cohort of patients with PN from the USA. Eligible participants were aged ā„ 18 years with a dermatologist diagnosis of PN presenting to the Johns Hopkins Itch Center between August 2017 and April 2019. Patients completed a paper-based survey that included two QoL instruments [Dermatology Life Quality Index (DLQI) and ItchyQoL], two pruritus-Āspecific severity instruments [worst-itch numerical rating scale (WI-NRS) and 5-D Pruritus Scale] and the Beck Depression Inventory (BDI). In total, 40 patients were surveyed. Demographic characteristics were collected by patient self-report and confirmed via medical records. Statistical analysis was performed in Stata version 15 (StataCorp, College Station, TX, USA). Differences between groups were determined by MannāWhitney U tests. Two sample t-tests with unequal variances were employed to compare mean QoL scores with published scores.
- Top Cited PapersOpen Access
- 19 January 2024
- Published byĀ ElsevierĀ inĀ Journal of Investigative Dermatology
- Vol.Ā 144 Ā (7) , 1568-1578.e5
Single-Cell RNA Sequencing Reveals Dysregulated POSTN+WNT5A+ Fibroblast Subclusters in Prurigo Nodularis
- 19 January 2024
- Published byĀ ElsevierĀ inĀ Journal of Investigative Dermatology
- Vol.Ā 144 Ā (7) , 1568-1578.e5
Top Cited PapersOpen AccessSingle-Cell RNA Sequencing Reveals Dysregulated POSTN+WNT5A+ Fibroblast Subclusters in Prurigo Nodularis
- Open Access
- 28 July 2023
- Published byĀ ElsevierĀ inĀ JAAD International
- Vol.Ā 13, 39-45
Risk of incident sleep disorders in patients with prurigo nodularis: A population-level analysis using The Health Improvement Network
- 28 July 2023
- Published byĀ ElsevierĀ inĀ JAAD International
- Vol.Ā 13, 39-45
Open AccessRisk of incident sleep disorders in patients with prurigo nodularis: A population-level analysis using The Health Improvement Network
- Open Access
- 5 May 2023
- Published byĀ ElsevierĀ inĀ JID Innovations
- Vol.Ā 3 Ā (4) , 100206
Topical GZ21T Inhibits the Growth of Actinic Keratoses in a UVB-Induced Model of Skin Carcinogenesis
- 5 May 2023
- Published byĀ ElsevierĀ inĀ JID Innovations
- Vol.Ā 3 Ā (4) , 100206
Open AccessTopical GZ21T Inhibits the Growth of Actinic Keratoses in a UVB-Induced Model of Skin Carcinogenesis